Clinical trial
MITIGATE-NeoBOMB1: A Phase I/IIa Study to Evaluate Safety, Biodistribution, Dosimetry+Preliminary Diagnostic Performance of 68Ga-NeoBOMB1 in Pat. With Advanced TKI-treated GIST Using Positron-emission Tomography/Computer Tomography (PET/CT)
NCT02931929 is registered in ClinicalTrials.gov with Medical University Innsbruck as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- MITIGATE-NeoBOMB1: A Phase I/IIa Study to Evaluate Safety, Biodistribution, Dosimetry+Preliminary Diagnostic Performance of 68Ga-NeoBOMB1 in Pat. With Advanced TKI-treated GIST Using Positron-emission Tomography/Computer Tomography (PET/CT)
- Lead sponsor
- Medical University Innsbruck
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- November 28, 2016
- Completion date
- April 9, 2019
- Enrollment
- 9 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.